Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the 10 potential takeover targets with strong price momentum. The appeal is not hard to see. The company is built around RAS-targeted oncology, and their daraxonrasib has become one of the most closely watched assets in that space.

The stock’s momentum has only strengthened the strategic case. Barron’s reported on April 13 that Revolution Medicines shares had already gained 164% over the prior year before jumping another 39% that day after new trial data.

Pressmaster/Shutterstock.com

The catalyst was daraxonrasib’s pivotal Phase 3 RASolute 302 result announced on April 13, 2026. Reuters reported that the drug helped previously treated metastatic pancreatic cancer patients live a median of 13.2 months, compared with 6.7 months for standard chemotherapy, while also improving progression-free survival. RBC said the drug could eventually generate more than $5 billion in U.S. sales.

Daraxonrasib’s strategic value had already drawn takeover attention. On January 8, 2026, Reuters reported that Merck was in talks to buy Revolution Medicines in a deal that could value the company at $28 billion to $32 billion. Earlier, the Wall Street Journal had reported AbbVie was near a deal, though AbbVie denied it to Reuters the next day. Later in January, Reuters reported that Merck was no longer in talks, but said another buyer could still emerge.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a late-stage clinical oncology company focused on developing targeted therapies for patients with RAS-addicted cancers.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.